Tacrolimus
Half-Life (t½) PO: 12h · IV: 12h
Formula C44H69NO12
Molecular Weight 804.02 g/mol
Aliases FK-506, Prograf, Advagraf Pharmacological Mechanism Binds FKBP-12 → inhibits calcineurin → same T-cell IL-2 suppression mechanism as cyclosporine but ~100× more potent per mg. CYP3A4 + P-gp substrate — interaction list as severe as cyclosporine. Displaced cyclosporine as preferred transplant immunosuppressant.
Half-Life & Elimination Curve (PO: 12h · IV: 12h) 100% 50% 25% 12.5% 0% 0h 0×t½ 12h 1×t½ 24h 2×t½ 36h 3×t½ 48h 4×t½ 60h 5×t½ 0×t½ (0h): 100% remaining (~0.283 µg/L) 1×t½ (12h): 50% remaining (~0.142 µg/L) 2×t½ (24h): 25% remaining (~0.0709 µg/L) 3×t½ (36h): 12.5% remaining (~0.0354 µg/L) 4×t½ (48h): 6.3% remaining (~0.0177 µg/L) 5×t½ (60h): 3.1% remaining (~0.00886 µg/L) Plasma (PO) t½ Decay (12h)
0×t½ 0h 100% (0.283 µg/L) 1×t½ 12h 50% (0.142 µg/L) 2×t½ 24h 25% (0.0709 µg/L) 3×t½ 36h 12.5% (0.0354 µg/L) 4×t½ 48h 6.3% (0.0177 µg/L) 5×t½ 60h 3.1% (0.00886 µg/L) Dosing Guidelines Oral (PO): Typical 0.167 mg (Range: 0.1–0.3 mg)Intravenous (IV): Typical 0.167 mg (Range: 0.1–0.3 mg)Transdermal (TD): Typical 0.167 mg (Range: 0.1–0.3 mg)Pharmacokinetic Parameters Oral (PO): Bioavailability (F): 20% · Volume of Distribution (Vd): 105 L · Absorption (ka): 1.77 h⁻¹ (t½ka ≈ 23m) [PMID 10348790 ]Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 105 L [PMID 17425625 ]Pathways It Modulates Target Organ Systems digestive Immune & Hematologic Interactions Schisandra (major): Raises tacrolimus AUC 2–3× via CYP3A4 + P-gp inhibition. [Giacomini 2010]St. John's Wort (contraindicated): CYP3A4 + P-gp induction → sub-therapeutic levels → rejection risk. [Markowitz 2003]Chemical Structure & Identifiers InChIKey: QJJXYPPXXYFBGM-LFZNUXCKSA-NSMILES: C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OCReferences Directory Compounds Registry Human Biology Hub